Head and Neck Malignant Paragangliomas: Experience from a Single Institution

2021 ◽  
pp. 014556132110523
Author(s):  
Yiming Ding ◽  
Lifeng Li ◽  
Demin Han ◽  
Shaozhong Wang ◽  
Xiaohong Chen
Keyword(s):  
Head And Neck ◽  
Postoperative Radiotherapy ◽  
Treatment Options ◽  
Gene Mutations ◽  
Cervical Lymph Node Metastasis ◽  
Clinicopathological Characteristics ◽  
Genetic Mutations ◽  
Comprehensive Treatment ◽  
Ki 67 ◽  
Malignant Paraganglioma

Objectives: To summarize the clinicopathological and genetic features of malignant paragangliomas in head and neck cancer and to explore the appropriate treatment options for this rare lesion. Methods: Six patients harboring head and neck malignant paraganglioma from Beijing Tongren Hospital were retrospectively reviewed. The clinicopathological characteristics, gene mutations, and prognosis of these patients were analyzed. Results: Of these 6 patients, 3 were male and 3 were female; 4 patients harbored malignant carotid body tumors, and two had malignant vagal paragangliomas. Three patients had cervical lymph node metastasis, two presented with lung and bone metastasis, and 1 had lung and liver metastasis. Of the 6 patients, four underwent surgical resection, and the other two patients denied surgery and instead received chemotherapy with paclitaxel, ifosfamide, and dacarbazine. These 2 patients with vagal paraganglioma received postoperative radiotherapy. All 6 patients are still alive at the present time, with a median follow-up time of 66 months. Positive Ki-67 expression in tumor tissue ranged from 1% to 40%. Genetic mutations in SDHD, SDHB, ATR, and MAP3K13 were identified in 4 patients. Conclusions: After comprehensive treatment, head and neck malignant paraganglioma can attain a favorable prognosis. Genetic mutations are commonly detected in patients with malignant paragangliomas. This study also identified mutations in ATR and MAP3K13 in these patients.

scholarly journals A rare case of myelodysplastic syndrome with refractory thrombocytopenia

2015 ◽  
Vol 7 (3) ◽  
Author(s):  
Waqas Jehangir ◽  
John Webb ◽  
Shilpi Singh ◽  
Sabrina Arshed ◽  
Shuvendu Sen ◽  
...  
Keyword(s):  
Rare Case ◽  
Treatment Options ◽  
Gene Mutations ◽  
Mortality Rates ◽  
Morbidity And Mortality ◽  
Genetic Mutations ◽  
Specific Gene ◽  
High Morbidity ◽  
Risk Patients ◽  
Evidenced Based

Myelodysplastic syndromes (MDS) represent a variety of clonal abnormalities, possibly preleukemic and display numerous phenotypic manifestations. Specific mutations carry high morbidity and mortality rates due to cell line dysplasia. MDS commonly presents with symptoms related to anemia, and approximately two-thirds will develop thrombocytopenia, a rare, but potentially lethal complication that increases complexity in treatment and morbidity, and may be due to unique genetic mutations leading to refractory thrombocytopenia, ultimately leading to an overall reduction in survival. Careful identification and monitoring of this patient subdivision can significantly reduce morbidity and mortality, and potential identification of specific gene mutations and advances in treatment options will hopefully provide guidance on detecting at-risk patients in the future. We present a case of a man with MDS-U (karyotype 46, XY, del (20) (q11.2q13.3) (20) with no detected <em>JAK2</em> <em>V617F</em> mutation), who in despite of appropriate evidenced based treatment, continued to exhibit refractory thrombocytopenia.

scholarly journals Expression and clinical significance of miR-3615 in hepatocellular carcinoma

2021 ◽  
Vol 49 (1) ◽  
pp. 030006052098154
Author(s):  
Xin Yuan ◽  
Yize Zhang ◽  
Zujiang Yu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Curve ◽  
Clinicopathological Characteristics ◽  
The Cancer Genome Atlas ◽  
Prognostic Information ◽  
Ki 67 ◽  
Tissue Samples ◽  
Expression Levels ◽  
Kaplan Meier ◽  
Serum Alpha Fetoprotein

Objective To investigate the association between microRNA-3615 (miR-3615) expression and the prognosis and clinicopathological features in patients with hepatocellular carcinoma (HCC). Methods We obtained clinicopathological and genomic data and prognostic information on HCC patients from The Cancer Genome Atlas (TCGA) database. We then analyzed differences in miR-3615 expression levels between HCC and adjacent tissues using SPSS software, and examined the relationships between miR-3615 expression levels and clinicopathological characteristics. We also explored the influence of miR-3615 expression levels on the prognosis of HCC patients using Kaplan–Meier survival curve analysis. Results Based on data for 345 HCC and 50 adjacent normal tissue samples, expression levels of miR-3615 were significantly higher in HCC tissues compared with adjacent tissues. MiR-3615 expression levels in HCC patients were negatively correlated with overall survival time and positively correlated with high TNM stage, serum Ki-67 expression level, and serum alpha-fetoprotein level. There were no significant correlations between miR-3615 expression and age, sex, and pathological grade. Conclusion MiR-3615 may be a promising new biomarker and prognostic factor for HCC.

High rates of postoperative radiotherapy delay in head and neck cancer before and after Medicaid expansion

Head & Neck ◽  
2021 ◽  
Author(s):  
John Pang ◽  
Farhoud Faraji ◽  
Erik Risa ◽  
Loren K. Mell ◽  
Jeffrey J. Houlton ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Postoperative Radiotherapy ◽  
Medicaid Expansion ◽  
Before And After

Adjuvant radiotherapy plus systemic chemotherapy in resected head and neck mucosal melanoma.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18042-e18042
Author(s):  
Rong Duan ◽  
Bixia Tang ◽  
Zhihong Chi ◽  
Chuanliang Cui ◽  
Bin Lian ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Head And Neck ◽  
Distant Metastasis ◽  
Adjuvant Radiotherapy ◽  
Postoperative Radiotherapy ◽  
Local Relapse ◽  
Mucosal Melanoma ◽  
Uicc Stage ◽  
Free Survival ◽  
Cox Analysis

e18042 Background: The median over survival (OS) of resected head and neck mucosal melanoma (HNMM) is 49.0 months. About 65% of patients experience local recurrence or distant metastasis after surgery. Therefore, adjuvant therapy is critical to improve the poor prognosis. Methods: Data regarding HNMMs with radical surgery (stage III-IVa, AJCC HNMM 8th version) between September 1, 2006 and February 28, 2020 at Peking University Cancer Hospital was collected retrospectively. Postoperative radiotherapy was usually prescribed as GTV 60-70Gy/CTV 60Gy/30f. Patients were divided into four groups by the adjuvant regimens: radiotherapy+chemotherapy (RC), chemotherapy (C), radiotherapy (R) and observation (O). Results: In total, 368 patients were enrolled, including 104 RC,114 C, 53 R, 97 O, respectively. After median follow-up of 63.9 mo (range: 0.9-146.7), the median local relapse-free survival (LRFS) was 10.1 mo (95%CI: 6.7-13.6) in the O group, as compared with 65.9 mo (95%CI: 31.7-100.1, P＜0.001) in the R group, 75.6 mo (95%CI: 50.1-101.0, P＜0.001) in the C group, and 84.6 mo (95%CI: 48.5-120.8, P＜0.001) in the RC group. The median distant metastasis-free survival (DMFS) was 13.7 mo (95%CI: 8.0-19.5) in the O group, 15.3 mo (95%CI: 8.7-21.9, P = 0.898) in the R group, as compared with 25.7 mo (95%CI: 14.6-36.8, P = 0.001) in the C group, 49.3 mo (95%CI: 32.6-66.0, P＜0.001) in the RC group. Estimated OS was 36.4 mo (95%CI: 24.0-48.8) in the O group, as compared with 30.8 mo (95%CI: 23.0-38.6, P = 0.733) in the R group, 40.8 mo (95%CI: 34.8-46.8, P = 0.289) in the C group, 58.2 mp (95%CI: 36.4-79.9, P = 0.002) in the RC group. Primary location, age, gender, UICC staging and adjuvant regimens were included for multivariate Cox analysis. With regard to OS, UICC stage and RC were the prognostic factors. With regard to DMFS, UICC stage, RC and C were the prognostic factors. With regard to LRFS, UICC stage, RC, R, C were the prognostic factors. Conclusions: It is the largest study on the role of adjuvant radiotherapy and chemotherapy on HNMM till now. The results demonstrate that postoperative radiotherapy improves LRFS but has no impact on DMFS, while adjuvant radiotherapy plus chemotherapy prolongs OS. It further validates the clinical practice of UICC stage of HNMM, which might shed lights on the study of the whole mucosal melanoma.

Gene mutations and clinical prognosis of mucosal melanoma in different locations of head and neck

2021 ◽  
pp. 1-6
Author(s):  
Wei Guo ◽  
Gaofei Yin ◽  
Chuanliang Cui ◽  
Yan Kong ◽  
Zhigang Huang ◽  
...  
Keyword(s):  
Head And Neck ◽  
Gene Mutations ◽  
Mucosal Melanoma ◽  
Clinical Prognosis

ORAL CANCER BIOCHEMICAL RESEARCH: CURRENT STATUS AND EMERGING FRONTIERS

2021 ◽  
Vol 1 (1) ◽  
pp. 10-16
Author(s):  
Radu Radulescu ◽  
Alexandra Totan ◽  
Daniela Miricescu ◽  
Maria Greabu
Keyword(s):  
Oral Cancer ◽  
Treatment Options ◽  
Growth Factor Receptor ◽  
B Cell Lymphoma ◽  
Current Status ◽  
Inflammatory Factors ◽  
Ki 67 ◽  
Proliferation Markers ◽  
Genomic Markers ◽  
Biochemical Research

Cancer represents one of the leading causes or mortality worldwide, oral cancer accounting for almost 9% of deaths, early diagnosis playing a crucial role. Salivary biomarkers analysis is proving to be an alternative diagnosis method. Oral cancer biomarkers can be compounds that play role in every aspect of malignancy from triggering factors to markers of progression, inflammation or invasiveness. There are numerous genomic markers, ranging from well known ones such as p16, p21, p27 and p53 genes, cyclin D1, EGFR gene (epidermal growth factor receptor), C-kit gene (KIT proto-oncogene, receptor tyrosine kinase), bcl-6(B-cell lymphoma 6 protein gene) to least studied ones such as OXSR1(oxidative stress-responsive kinase-1gene). Proteomic markers range from inflammatory factors such as interleukins IL-8 and Il-6, transcription factors such as FOXO3 (forkhead box O3) protein and S100B protein, matrix metalloproteinases (MMP) involved in extracellular matrix degradation and their inhibitors (TIMP - tissue inhibitor of metalloproteinases), specific proliferation markers such as Ki-67 protein and many more. Developing saliva based oral cancer screening and prognosis tests may lead to better treatment options.

PREVALANCE OF HEAD AND NECK CANCER IN UPPER ASSAM: AN INSTITUTIONAL STUDY.

2021 ◽  
pp. 50-51
Author(s):  
Ayesha Agarwal ◽  
Trishan Paul ◽  
Rudra Kanta Gogoi ◽  
Rheetwik Baruah ◽  
Chiranjeev Baruah
Keyword(s):  
Oral Cavity ◽  
Head And Neck ◽  
Treatment Options ◽  
Population Based ◽  
Population Based Study ◽  
Medical College ◽  
Starting Point ◽  
High Prevalence ◽  
North Eastern ◽  
Total Body

In India, head and neck cancers (HNCA) account for 14.3% cancers at all sites. In North-eastern India, there is a high prevalence of HNCA which can be associated with pervasive habit of using tobacco, lime and betel. The alarmingly high prevalence of cancers of head and neck in this part of India has prompted us to take up this study. Ahospital-based study on prevalence of cancer in various head and neck regions like oropharynx, oral cavity, pharynx, larynx, salivary glands and nasal cavity was conducted in Department of Radiation Oncology, Assam Medical College and Hospital from June 2020 to May 2021.The prevalence is found to be signicantly high at 57.59%, affecting males more than females in the age group of 50-59 years. HNCA of hypopharynx and oral cavity constituted a major burden of total body cancer. This study hopes to quantify and analyse the HNCAspectrum and should help as a starting point for a much needed population based study in this region. Acomprehensive effort is required to identify the cause of such high prevalence of HNCAin this region of India, generate awareness and treatment options suited to meet this challenge.

scholarly journals Primary maxillofacial chordoma: a rare case report and literature review

2019 ◽  
Vol 47 (9) ◽  
pp. 4575-4579
Author(s):  
Yu Cui ◽  
Xiang-yan Cui ◽  
Tingting Yu ◽  
Zhan-peng Zhu ◽  
Xin Wang
Keyword(s):  
Adjuvant Radiotherapy ◽  
Rare Case ◽  
Postoperative Radiotherapy ◽  
Eastern Cooperative Oncology Group ◽  
Treatment Strategies ◽  
Comprehensive Treatment ◽  
Neck Lymph Node ◽  
Group Score ◽  
Rare Case Report

Primary maxillofacial chordoma is extremely rare. We herein report a very rare case of a recurrent maxillofacial chordate tumor that was diagnosed in a 56-year-old woman who underwent three tumor resections. After surgical treatment, the patient healed well with an Eastern Cooperative Oncology Group score of 1. She was discharged to a local hospital for adjuvant radiotherapy. Close follow-up was ongoing at the time of this writing. Radical surgery and adjuvant radiotherapy remain the main treatment strategies for chordoma. Postoperative radiotherapy is particularly important. Our experience is to administer a total dose of 50 Gy to a clearly delineated target. If appropriate comprehensive treatment is available, distant metastasis of primary chordoma is rare, and neck dissection is therefore not generally recommended. Neck lymph node dissection is generally not recommended.

Sign in / Sign up

Export Citation Format

Share Document